New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.
Fiche publication
Date publication
janvier 2015
Journal
Experimental hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr BORG Christophe, Pr DECONINCK Eric, Dr FERRAND Christophe, Pr GARNACHE-OTTOU Francine, Dr GODET Yann, Dr LAROSA Fabrice, Pr TOUSSIROT Eric
Tous les auteurs :
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C
Lien Pubmed
Résumé
CD20 is a B cell lineage-specific marker expressed by normal and leukemic B cells and targeted by several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant (D393-CD20) is expressed at various levels in leukemic B cells or lymphoma B cells but not in resting, sorted B cells from the peripheral blood of healthy donors.
Mots clés
Alternative splicing, B malignancies, CD20, CLL, EBV transformation
Référence
Exp Hematol Oncol. 2015 ;5:7